Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Bone health in patients with type 2 diabetes treated by Roux-En-Y gastric bypass and the role of diabetes remission

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Genetic Determinants of Weight Loss After Bariatric Surgery

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Plasma FGF-19 Levels are Increased in Patients with Post-Bariatric Hypoglycemia

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. The Impact of Upper Abdominal Pain During Pregnancy Following a Gastric Bypass

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Vagal Blocking for Obesity Control: a Possible Mechanism-Of-Action

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Fracture-induced changes in biomarkers CTX, PINP, OC, and BAP - a systematic review

    Research output: Contribution to journalReviewResearchpeer-review

  2. Multiple Fractures and Impaired Bone Fracture Healing in a Patient with Pycnodysostosis and Hypophosphatasia

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Assessment of acute bone loading in humans using [18F]NaF PET/MRI

    Research output: Contribution to journalJournal articleResearchpeer-review

  • Lene Ring Madsen
  • Rasmus Espersen
  • Marie Juul Ornstrup
  • Niklas Rye Jørgensen
  • Bente Lomholt Langdahl
  • Bjørn Richelsen
View graph of relations

BACKGROUND: Roux-en-Y gastric bypass (RYGB) has been associated with negative effects on bone. Whether this association is affected by pre-surgical type 2 diabetes (T2D) and surgically induced diabetes remission is unknown.

METHODS: In this cross-sectional, matched cohort study 6 years after RYGB, we investigated bone health in 96 individuals with body mass index (BMI) > 35 kg/m2 and T2D (stratified on current diabetes status) treated by RYGB 6 years earlier compared with 49 non-operated individuals with T2D matched with respect to sex, age, and current BMI. Main outcome measures were areal and volumetric bone mineral density (aBMD and vBMD), bone turnover, and odds ratio of osteoporosis/osteopenia.

RESULTS: The RYGB group had lower hip (0.916 vs 1.010 g/cm2, p < 0.001), forearm (0.497 g/cm2 vs 0.554 g/cm2, p < 0.001) aBMD, (269.63 mg/cm3 vs 306.07 mg/cm3, p < 0.001) tibial, and radial (238.57 mg/cm3 vs 278.14 mg/cm3, p < 0.0001) vBMD than the control group. Relative to the control group, c-terminal cross-linked telopeptide, procollagen type I amino-terminal propeptide, and osteocalcin were 75%, 41%, and 72% higher in the RYGB group, respectively (all p < 0.001). Odds ratio for osteopenia/osteoporosis in operated individuals was 2.21 (95% CI 1.06; 4.79, p = 0.05). Overall, stratified analysis on current diabetes status did not alter these outcomes.

CONCLUSIONS: Individuals with T2D treated by RYGB, compared to individuals with T2D of similar age and body composition not treated by RYGB, have lower BMD, lower bone strength, and increased levels of several bone turnover markers. Bone health was not associated with current diabetes status in the RYGB group.

Original languageEnglish
JournalObesity Surgery
Volume29
Issue number6
Pages (from-to)1823-1831
Number of pages9
ISSN0960-8923
DOIs
Publication statusPublished - Jun 2019

ID: 58197339